EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Long‐Term Survival Obtained by Repeated Cytoreductive Surgery and S‐1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report

Masayasu Urushibara iD, Daisuke Kato iD, Taisuke Okumura iD, Akihiro Kojima iD, Yuichiro Kato iD, Takeshi Shirakawa iD, Yohei Shimizu iD, Tsunehiro Nenohi iD, Yuki Matsumoto iD, Noriyuki Matsutani iD, Tatsuya Aso iD, Mikiko Takahashi iD und 2 weitere

Cancer Reports · 2025

DOI: 10.1002/cnr2.70317 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Masayasu Urushibara und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Teikyo University Hospital, Mizonokuchi, Kawasaki City, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Cytoreduction Surgical Procedures, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urachal carcinoma (URC) is a rare tumor of the urinary bladder, of which the histology usually resembles that of colorectal adenocarcinoma. Achievement of cure in patients with metastatic URC is difficult, and the survival rate of these patients has remained unsatisfactory despite various efforts. Case A 74‐year‐old female patient presented to us complaining of gross hematuria. Abdominal and thoracic computed tomography revealed a mass in the dome of the bladder with a single lung nodule. The two tumors, which were resected by partial cystectomy and video‐assisted thoracic surgery, respectively, were diagnosed by postoperative histopathology as adenocarcinomas. Subsequent to the surgeries, bilateral ovarian metastases and another lung metastasis, which appeared metachronously, were also resected. The repeated cytoreductive surgery combined with administration of S‐1 plus cisplatin chemotherapy at each instance of disease progression eventually yielded a durable progression‐free survival; even at 5 years after the initial therapy, the patient remained asymptomatic with no limitation of activities despite the failure to achieve “cure”.

Conclusion

Not only some degree of sensitivity of the tumor to chemotherapy, but also the repeated cytoreductive surgeries might allow prolonged survival with a good quality of life in elderly patients with metastatic URC, even in the absence of cure and failure of genetic testing to suggest any potentially effective second‐line drugs. To improve the survival of patients with metastatic URC, complementary therapy suggested by the results of genomic profiling may be necessary along with other multimodality therapy, including sequential metastasectomy and chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCytoreduction Surgical ProceduresLung NeoplasmsOvarian NeoplasmsAdenocarcinomaHumansFemaleCisplatinAgedDrug CombinationsTegafurOxonic AcidDisease ProgressionCystectomyCombined Modality Therapy

Stichwörter der Autor:innen

chemotherapylong survivalmetastasectomymetastasismultimodality treatmenturachal carcinoma

Substanzen

CisplatinDrug CombinationsTegafurOxonic AcidS 1 (combination)

Autor:innen und Institutionen

  • Department of Urology, Teikyo University Hospital, Mizonokuchi, Kawasaki City, Japan.
  • Department of Urology, Nissan Tamagawa Hospital, Tokyo, Japan.
  • Department of Surgery, Teikyo University Hospital, Mizonokuchi, Kawasaki City, Japan.
  • Department of Diagnostic Pathology, Teikyo University Hospital, Mizonokuchi, Kawasaki City, Japan.

ORCID-Profile: Masayasu Urushibara, Daisuke Kato, Taisuke Okumura, Akihiro Kojima, Yuichiro Kato, Takeshi Shirakawa, Yohei Shimizu, Tsunehiro Nenohi, Yuki Matsumoto, Noriyuki Matsutani, Tatsuya Aso, Mikiko Takahashi, Kazuhiro Ishizaka, Minato Yokoyama

Zitieren

APA

Urushibara, M., Kato, D., Okumura, T., Kojima, A., Kato, Y., Shirakawa, T., Shimizu, Y., Nenohi, T., Matsumoto, Y., Matsutani, N., Aso, T., Takahashi, M., Ishizaka, K., & Yokoyama, M. (2025). Long‐Term Survival Obtained by Repeated Cytoreductive Surgery and S‐1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report. Cancer Reports. https://doi.org/10.1002/cnr2.70317

Vancouver

Urushibara M, Kato D, Okumura T, Kojima A, Kato Y, Shirakawa T, et al. Long‐Term Survival Obtained by Repeated Cytoreductive Surgery and S‐1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report. Cancer Reports. 2025. doi:10.1002/cnr2.70317

BibTeX
@article{Urushibara2025,
  author = {Urushibara, Masayasu and Kato, Daisuke and Okumura, Taisuke and Kojima, Akihiro and Kato, Yuichiro and Shirakawa, Takeshi and Shimizu, Yohei and Nenohi, Tsunehiro and Matsumoto, Yuki and Matsutani, Noriyuki and Aso, Tatsuya and Takahashi, Mikiko and Ishizaka, Kazuhiro and Yokoyama, Minato},
  title = {Long‐Term Survival Obtained by Repeated Cytoreductive Surgery and S‐1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70317}
}
Kostenlos starten →